SCHEMBL5923099

SCHEMBL5923099

COc1cc(OC)nc(NC(=N)Nc2cccc(Oc3ccccc3)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MITF O75030 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ PLAU P00749 1/20 0.46
▸ MAPT P10636 5/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ HPGD P15428 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NLRP3 Q96P20 1/20 0.42
▸ RAF1 P04049 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923153 0.93 HTT (0.46) MITFALDH1A1POLBMAPK1HTT
SCHEMBL5923231 0.90 SMN1; SMN2 (0.50) ALDH1A1POLBHTTKMT2AMEN1
SCHEMBL5923172 0.85 MAPK1 (0.50) MAPK1KMT2AMEN1LMNA
SCHEMBL5923055 0.85 RAB9A (0.49) MITFALDH1A1POLBMAPK1HTT
SCHEMBL5923213 0.85 VSIR (0.50) POLBKMT2AMEN1MAPTTP53
SCHEMBL5923234 0.83 SMN1; SMN2 (0.48) ALDH1A1POLBHTTKMT2AMEN1
SCHEMBL5923340 0.81 MAPT (0.44) POLBHTTKMT2AMAPTRAB9A
SCHEMBL5923406 0.80 MEN1 (0.48) MITFALDH1A1POLBMAPK1HTT
SCHEMBL5923220 0.79 MAPK1 (0.54) ALDH1A1POLBMAPK1HTTKMT2A
SCHEMBL5923131 0.79 MAPT (0.46) ALDH1A1HTTKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication PIGS, GUCY1A1, GUCY1B1 MITF 3296/4885ALDH1A1 535/4885POLB 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback